Comparative analysis of all-cause health care resource utilization and costs among patients with non-valvular atrial fibrillation and high risk of gastrointestinal bleeding in France: a nationwide cohort analysis
In patients at high-risk of GIB, DOACs were associated with reduced direct HCRU costs compared to VKAs. Among DOACs, apixaban was associated with reduced direct HCRU costs.
Authors
- Nadia Quignot (ORCID: https://orcid.org/0000-0001-8718-1307)
- Artak Khachatryan (ORCID: https://orcid.org/0000-0003-3888-2347)
- Gaëlle Gusto
- Giancarlo Pesce (ORCID: https://orcid.org/0000-0003-4925-6325)
- Ruth Mokgokong (ORCID: https://orcid.org/0000-0002-6278-4969)
- Feng Dai (ORCID: https://orcid.org/0000-0002-9963-6863)
- Fouad Sedjelmaci
- José Chaves (ORCID: https://orcid.org/0000-0003-3820-3009)
Institutions
- Pfizer (United States) (US)
- IQVIA (United Kingdom) (GB)
- Pfizer (France) (FR)
- Health Economics and Outcomes Research (United Kingdom) (GB)
- Pfizer (Spain) (ES)
- Metropolitana Milanese (Italy) (IT)
- IQ Solutions (US)
- Organisation Mondiale de la Santé Animale (FR)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2025-08-05
- DOI
- https://doi.org/10.1080/13696998.2025.2543214
- Primary Topic
- Atrial Fibrillation Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00